Efficacy and safety of peginterferon-α2b and ribavirin combination therapy in children with chronic hepatitis C infection

Pediatric Infectious Disease Journal

Volumn 27, Issue 2, 2008, Pages 142-148

  Jara, Paloma ^a,b   Hierro, Loreto ^a   Vega, Angela De La ^a   Díaz, Carmen ^a   Camarena, Carmen ^a   Frauca, Esteban ^a   Muñoz Bartolo, Gema ^a   Díez Dorado, Ruth ^a   De Guevara, Concepción Ladrón ^b   Larrauri, Javier ^b   Rueda, Magdalena ^c  

^a Pediatric Liver Service   (United Kingdom)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Schering Plough SA   (Spain)

Author keywords

Combination treatment; HCV infection; Pediatrics

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2B INTERFERON; PEGINTERFERON ALFA-2B; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; CONSTIPATION; DECREASED APPETITE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EPISTAXIS; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL INFECTION; HAIR LOSS; HALLUCINATION; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTHYROIDISM; INJECTION SITE ERYTHEMA; IRRITABILITY; MOUTH PAIN; MYALGIA; NAUSEA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN INFECTION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; VOMITING; WEIGHT REDUCTION; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; MALE; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; RIBAVIRIN;

EID: 40949100976     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318159836c     Document Type: Article

References (37)

1. Gessoni G, Manoni F. Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area: a seroepidemiological study. Eur J Med. 1993;2:79-82.
2. Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics. 1998;101:481-485.
3. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002;36:S106-S113.
4. Resti M, Jara P, Hierro L, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol. 2003;70: 373-377.
5. The European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005;41:45-51.
6. Alberti A, Benvegnu L. Management of hepatitis C.. J Hepatol 2003; 38(Suppl 1):S104-S118.
7. Guido M, Bortolotti F, Leandro G, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol. 2003;98:660-663.
8. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004;53:1504-1508.
9. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
10. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.
11. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C.. Hepatology 2002;36(5 Suppl 1):S121-S127.
12. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C.. N Engl J Med 2000;343:1666-1672.
13. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.. Hepatology 2001;34:395-403.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: 958-965.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-982.
16. Gonzalez-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005;42: 1010-1018.
17. Christensson B, Wiebe T, Akesson A, Widell A. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis. 2000;30:585-586.
18. Lackner H, Moser A, Deutsch J, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics. 2000;106:E53.
19. Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002;36:1280-1284.
20. Jara P, Hierro L, Frauca E, et al. Interferon alfa-2b treatment in children with chronic HCV hepatitis. JPediatr Gastroenterol Nutr. 1997;24:487.
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
22. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938.
23. Jonas MM. Children with hepatitis C.. Hepatology 2002;36(5 Suppl 1):S173-S178.
24. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.. Hepatology 2005;41:1013-1018.
25. Iorio R, Pensati P, Botta S, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J. 1997;16:984-990.
26. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002;34:52-58.
27. Gregorio GV, Pensati P, Iorio R, et al. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 1998;112:471-476.
28. Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol. 1999;31: 210-216.
29. Bortolotti F, Muratori L, Jara P, et al. Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr. 2003;142:185-190.
30. Iorio R, Giannattasio A, Vespere G, Vegnente A. LKM1 antibody and interferon therapy in children with chronic hepatitis C. J Hepatol 2001;35:685-687.
31. Duclos-Vallee JC, Nishioka M, Hosomi N, et al. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection. J Hepatol. 1998;28:965-970.
32. Todros L, Saracco G, Durazzo M, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology. 1995;22:1374-1378.
33. Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut. 2001;49:423-430.
34. Badizadegan K, Jonas MM, Ott MJ, Nelson SP, Perez Atayde AR. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology. 1998;28:1416-1423.
35. Guido M, Rugge M, Jara P, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology. 1998;115:1525-1529.
36. Hoshiyama A, Kimura A, Fujisawa T, Kage M, Kato H. Clinical and histologic features of chronic hepatitis C virus infection after blood transfusion in Japanese children. Pediatrics. 2000;105:62-65.
37. Rumbo C, Fawaz RL, Emre SH, et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr. 2006;43:209-216.